Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

NCT00061178 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No patients were enrolled, study cancelled before start

Conditions

Renal Cell Cancer

Interventions

DRUG: rhuMAb VEGF (Bevacizumab)

Sponsor

Genentech, Inc.